Thymosin Alpha-1 is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
Thymosin Alpha-1 (Thymosin alpha 1 (28-amino acid peptide)) is researched primarily for immune activation, T-cell function enhancement, antiviral response, cancer immunotherapy adjuvant. The only FDA-approved thymic peptide with specific orphan drug indications — approved in 35 countries, making it the most globally validated immune peptide therapeutic. It belongs to the Thymic peptide, immunomodulator category of compounds.
What Is Thymosin Alpha-1?
Thymosin Alpha-1 (Thymosin alpha 1 (28-amino acid peptide)) is a Thymic peptide, immunomodulator. Naturally occurring peptide isolated from thymus gland; synthetic form (thymalfasin/Zadaxin) developed for immune enhancement.
The only FDA-approved thymic peptide with specific orphan drug indications — approved in 35 countries, making it the most globally validated immune peptide therapeutic. It has attracted significant research interest for its potential effects on immune activation, T-cell function enhancement, antiviral response, cancer immunotherapy adjuvant.
How Does Thymosin Alpha-1 Produce These Benefits?
Engages Toll-like receptors (TLR) on myeloid and plasmacytoid dendritic cells, triggering MyD88-dependent signaling cascades. Drives IL-2 production, IFN-gamma stimulation, and T lymphocyte/NK cell activation while promoting thymopoiesis. Simultaneously suppresses pro-inflammatory IL-6/TNF-alpha while enhancing anti-inflammatory IL-10.
This multi-pathway activity is why Thymosin Alpha-1 shows potential across several different applications rather than being limited to a single use case.
Can Thymosin Alpha-1 Help With Immune Activation?
Research suggests Thymosin Alpha-1 may support immune activation through its thymic peptide, immunomodulator activity. FDA-approved as orphan drug for melanoma, DiGeorge syndrome, chronic hepatitis B, and hepatocellular carcinoma. Clinical trials ongoing for lung cancer, hepatitis C, HIV, and COVID-19. Approved in 35 countries.
Protocols targeting immune activation typically use 1.6-6.4 mg per dose administered twice weekly for 5-7 day injection cycles, repeated as needed.
Can Thymosin Alpha-1 Help With T-Cell Function Enhancement?
Research suggests Thymosin Alpha-1 may support T-cell function enhancement through its thymic peptide, immunomodulator activity. FDA-approved as orphan drug for melanoma, DiGeorge syndrome, chronic hepatitis B, and hepatocellular carcinoma. Clinical trials ongoing for lung cancer, hepatitis C, HIV, and COVID-19. Approved in 35 countries.
Protocols targeting T-cell function enhancement typically use 1.6-6.4 mg per dose administered twice weekly for 5-7 day injection cycles, repeated as needed.
Can Thymosin Alpha-1 Help With Antiviral Response?
Research suggests Thymosin Alpha-1 may support antiviral response through its thymic peptide, immunomodulator activity. FDA-approved as orphan drug for melanoma, DiGeorge syndrome, chronic hepatitis B, and hepatocellular carcinoma. Clinical trials ongoing for lung cancer, hepatitis C, HIV, and COVID-19. Approved in 35 countries.
Protocols targeting antiviral response typically use 1.6-6.4 mg per dose administered twice weekly for 5-7 day injection cycles, repeated as needed.
Can Thymosin Alpha-1 Help With Cancer Immunotherapy Adjuvant?
Research suggests Thymosin Alpha-1 may support cancer immunotherapy adjuvant through its thymic peptide, immunomodulator activity. FDA-approved as orphan drug for melanoma, DiGeorge syndrome, chronic hepatitis B, and hepatocellular carcinoma. Clinical trials ongoing for lung cancer, hepatitis C, HIV, and COVID-19. Approved in 35 countries.
Protocols targeting cancer immunotherapy adjuvant typically use 1.6-6.4 mg per dose administered twice weekly for 5-7 day injection cycles, repeated as needed.
Can Stacking Enhance Thymosin Alpha-1 Benefits?
Synergizes with interferons and antivirals for enhanced immune priming. Off-label stacking with checkpoint inhibitors in cancer immunotherapy.
See our Thymosin Alpha-1 stacking guide for detailed combination protocols.
What Is the Bottom Line on Thymosin Alpha-1 Benefits?
Thymosin Alpha-1 is researched for immune activation, T-cell function enhancement, antiviral response, cancer immunotherapy adjuvant. The evidence base includes: FDA-approved as orphan drug for melanoma, DiGeorge syndrome, chronic hepatitis B, and hepatocellular carcinoma. Clinical trials ongoing for lung cancer, hepatitis C, HIV, and COVID-19. Approved in 35 countries.
Thymosin Alpha-1 is fda-approved (zadaxin) for specific cancer and hepatitis indications. prescription medication. Source from reputable vendors with third-party testing for reliable results.
Complete Guide
Thymosin Alpha-1 : Benefits, Dosage, Side Effects & Research
Related Reading
- Thymosin Alpha-1 Dosage Guide
- Thymosin Alpha-1 Side Effects
- Thymosin Alpha-1 Stacking Guide
- Thymosin Alpha-1 Cycle Guide
- Thymosin Alpha-1 Research
- AOD-9604 Complete Guide
Calculate Your Thymosin Alpha-1 Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for Thymosin Alpha-1.
Open Calculator →Research-Grade Sourcing
If you're going to research Thymosin Alpha-1, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is Thymosin Alpha-1?
Thymosin Alpha-1 (Thymosin alpha 1 (28-amino acid peptide)) is a Thymic peptide, immunomodulator. Naturally occurring peptide isolated from thymus gland; synthetic form (thymalfasin/Zadaxin) developed for immune enhancement. It is researched for immune activation, T-cell function enhancement, antiviral response, cancer immunotherapy adjuvant.
What is the recommended Thymosin Alpha-1 dosage?
Common dosages: 1.6-6.4 mg per dose administered twice weekly via subcutaneous injection. Cycle length: 5-7 day injection cycles, repeated as needed. Half-life: not established. Use our peptide calculator for exact reconstitution math.
What are the side effects of Thymosin Alpha-1?
Well-tolerated. Local injection site reactions most common. Safe in liver disease, cancer, and autoimmune conditions. No significant organ toxicity.
Is Thymosin Alpha-1 safe?
Thymosin Alpha-1 has shown a favorable safety profile in research. FDA-approved (Zadaxin) for specific cancer and hepatitis indications. Prescription medication. All research should follow appropriate safety protocols.